Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum

Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinum

<p>Abstract</p> <p>Background</p> <p>Combination of platinum derivatives with paclitaxel is currently the standard front line regimen for patients with epithelial ovarian carcinoma, and represents also an active regimen in patients with metastatic breast or unknown prim...

Full description

Bibliographic Details
Main Authors:	Tichá Alena, Kalábová Hana, Dvořák Josef, Dragounová Emanuela, Hyšpler Radomír, Melichar Bohuslav
Format:	Article
Language:	English
Published:	BMC 2007-08-01
Series:	BMC Cancer
Online Access:	http://www.biomedcentral.com/1471-2407/7/155

Similar Items

Urinary Neopterin in Patients with Ovarian Cancer
by: Melichar Bohuslav, et al.
Published: (2006-11-01)

Gastrointestinal Permeability - a Parameter of Possible Prognostic Importance in Metastatic Colorectal Carcinoma
by: Melichar Bohuslav, et al.
Published: (2008-02-01)

Urinary Neopterin in Patients Treated with Gefitinib
by: Kalabova Hana, et al.
Published: (2007-02-01)

Serial Urinary Neopterin Measurements Reflect the Disease Course in Patients with Epithelial Ovarian Carcinoma Treated with Paclitaxel/Platinum Chemotherapy
by: Melichar Bohuslav, et al.
Published: (2007-02-01)

Serum Uric Acid and C-reactive Protein in Patients with Metastatic Colorectal Carcinoma During Combination Therapy with High-dose Folinic Acid
by: Melichar Bohuslav, et al.
Published: (2012-02-01)

Polyunsaturated Fatty Acids, Phytosterols and Cholesterol Metabolism in the Mediterranean Diet
by: Zdeněk Zadák, et al.
Published: (2006-01-01)

Urinary Neopterin, Serum Retinol, α-tocopherol and Homocysteine in Breast Cancer Patients During Treatment with Bevacizumab and Chemotherapy
by: Melichar Bohuslav, et al.
Published: (2010-02-01)

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma
by: Jindrich Kopecky, et al.
Published: (2018-11-01)

Systemic Immune Activation, Anemia and Thrombocytosis in Breast Cancer Patients Treated by Doxorubicin and Paclitaxel
by: Melichar Bohuslav, et al.
Published: (2006-11-01)

Changes in cholesterol metabolism during acute upper gastrointestinal bleeding: liver cirrhosis and non cirrhosis compared
by: Vladimir Hrabovsky, et al.
Published: (2019-09-01)

The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2020-09-01)

Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas
by: Roberta Affatato, et al.
Published: (2022-05-01)

Cyclo-oxygenase-2 (Cox-2) expression and resistance to platinum versus platinum/paclitaxel containing chemotherapy in advanced ovarian cancer
by: Paglia Amelia, et al.
Published: (2006-07-01)

The Energetic and Metabolic Effect of Ringerfundin (B. Braun) Infusion and Comparison with Plasma-Lyte (Baxter) in Healthy Volunteers
by: Zdeněk Zadák, et al.
Published: (2010-01-01)

Folate receptor: a potential target in ovarian cancer
by: Bartouskova Marie, et al.
Published: (2015-03-01)

Weekly Paclitaxel versus Three-Weekly Paclitaxel in Recurrent Platinum-Resistant Epithelial Ovarian and Peritoneal Cancers: A Phase III Study
by: Mohammed A. Osman, et al.
Published: (2016-01-01)

Metformin Improves Ovarian Cancer Sensitivity to Paclitaxel and Platinum-Based Drugs: A Review of In Vitro Findings
by: Giovanni Tossetta
Published: (2022-10-01)

Retraction Note: The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer
by: Hong Zhao, et al.
Published: (2021-02-01)

Comparison of performance of composite biomarkers of inflammatory response in determining the prognosis of breast cancer patients
by: Melichar Bohuslav, et al.
Published: (2017-12-01)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
by: Zweifel, M, et al.
Published: (2011)

Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer
by: Hanieh Meteran, et al.
Published: (2024-02-01)

Off-label use of paclitaxel and pembrolizumab in a case of platinum refractory epithelial ovarian cancer and extensive thromboembolism
by: Clarissa Lam, et al.
Published: (2022-06-01)

Integrated analysis of gene expression profiles associated with response of platinum/paclitaxel-based treatment in epithelial ovarian cancer.
by: Yong Han, et al.
Published: (2012-01-01)

CHFR and Paclitaxel Sensitivity of Ovarian Cancer
by: Andrea E. Wahner Hendrickson, et al.
Published: (2021-11-01)

Urinary neopterin concentrations during radiotherapy for gynecological cancer
by: Trivedi Sachin Vipin, et al.
Published: (2014-04-01)

Correlation of Peripheral Blood CD14+CD16+ Monocytes, Urinary Neopterin and the Risk Factors of Atherosclerosis in Patients with Breast Carcinoma
by: Králíčková Pavlína, et al.
Published: (2011-02-01)

Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer
by: Moore Carla L, et al.
Published: (2010-03-01)

Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts
by: Francesca Ricci, et al.
Published: (2017-05-01)

Interactions Between Anti-Vegf Therapy and Antitumor Immunity as a Potential Therapeutic Strategy in Colorectal Cancer
by: David Buka, et al.
Published: (2019-01-01)

Clinical trials and progress with paclitaxel in ovarian cancer
by: Sanjeev Kumar, et al.
Published: (2010-11-01)

Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells
by: Yifat Koren Carmi, et al.
Published: (2024-06-01)

Inhibition of Notch signaling in combination with paclitaxel reduces platinum-resistant ovarian tumor growth
by: Jolijn W Groeneweg, et al.
Published: (2014-07-01)

Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer
by: Vanita Noronha, et al.
Published: (2012-01-01)

Phase IB dose-escalation and expansion study of AKT kinase inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer
by: Blagden, S, et al.
Published: (2018)

SLIDE—Novel Approach to Apocrine Sweat Sampling for Lipid Profiling in Healthy Individuals
by: Aleš Kvasnička, et al.
Published: (2021-07-01)

Ovarian Cancer—Insights into Platinum Resistance and Overcoming It
by: Andrei Havasi, et al.
Published: (2023-03-01)

ATR Inhibitors in Platinum-Resistant Ovarian Cancer
by: Siyu Li, et al.
Published: (2022-11-01)

Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
by: Eduardo Gonzalez-Ochoa, et al.
Published: (2023-07-01)

Cell-permeable lanthanide-platinum(IV) anti-cancer prodrugs
by: Yao, K, et al.
Published: (2021)

Systemic immune response and peripheral blood cell count in patients with a history of breast cancer
by: Šrámek Vlastislav, et al.
Published: (2013-12-01)